BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 12377645)

  • 41. Pharmacokinetic and pharmacodynamic effects of oral eniluracil, fluorouracil and leucovorin given on a weekly schedule.
    Guo XD; Harold N; Saif MW; Schuler B; Szabo E; Hamilton JM; Monahan BP; Quinn MG; Cliatt J; Nguyen D; Grollman F; Thomas RR; McQuigan EA; Wilson R; Takimoto CH; Grem JL
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):79-85. PubMed ID: 12707718
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
    Calvo E; Cortés J; González-Cao M; Rodríguez J; Aramendía JM; Fernández-Hidalgo O; Martín-Algarra S; Salgado JE; Martínez-Monge R; de Irala J; Brugarolas A
    Oncology; 2002; 63(3):254-65. PubMed ID: 12381905
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
    Choi CW; Choi IK; Seo JH; Kim BS; Kim JS; Kim CD; Um SH; Kim JS; Kim YH
    Am J Clin Oncol; 2000 Aug; 23(4):425-8. PubMed ID: 10955877
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacology of fluorinated pyrimidines: eniluracil.
    Baker SD
    Invest New Drugs; 2000 Nov; 18(4):373-81. PubMed ID: 11081573
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
    Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
    Gibson MK; Holcroft CA; Kvols LK; Haller D
    Oncologist; 2005 Feb; 10(2):132-7. PubMed ID: 15709215
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
    J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
    Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ
    Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer].
    Taïeb J; Lecomte T; Ezenfis J; Artru P; Mitry E; Boige V; Clavero-Fabri MC; Vaillant JN; Rougier P; Ducreux M
    Gastroenterol Clin Biol; 2002; 26(6-7):605-9. PubMed ID: 12193860
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
    Schmidt J; Abel U; Debus J; Harig S; Hoffmann K; Herrmann T; Bartsch D; Klein J; Mansmann U; Jäger D; Capussotti L; Kunz R; Büchler MW
    J Clin Oncol; 2012 Nov; 30(33):4077-83. PubMed ID: 23008325
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study.
    Ahmed S; Vaitkevicius VK; Zalupski MM; Du W; Arlauskas P; Gordon C; Kellogg C; Shields AF
    Am J Clin Oncol; 2000 Aug; 23(4):420-4. PubMed ID: 10955876
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin.
    Sporn JR; Buzaid AC; Slater D; Cohen N; Greenberg BR
    Am J Clin Oncol; 1997 Feb; 20(1):81-3. PubMed ID: 9020295
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The French experience with infusional 5-FU in gastric and pancreatic cancer.
    Ducreux M; Rougier P
    J Infus Chemother; 1996; 6(4):203-5. PubMed ID: 9229316
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma.
    André T; Lotz JP; Bouleuc C; Azzouzi K; Houry S; Hannoun L; See J; Esteso A; Avenin D; Izrael V
    Ann Oncol; 1996 Feb; 7(2):173-8. PubMed ID: 8777174
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.
    Maisey N; Chau I; Cunningham D; Norman A; Seymour M; Hickish T; Iveson T; O'Brien M; Tebbutt N; Harrington A; Hill M
    J Clin Oncol; 2002 Jul; 20(14):3130-6. PubMed ID: 12118027
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase II study of sequential methotrexate and 5-fluorouracil in metastatic pancreatic cancer.
    Ikeda M; Okada S; Ueno H; Okusaka T; Tanaka N; Kuriyama H; Yoshimori M
    Hepatogastroenterology; 2000; 47(33):862-5. PubMed ID: 10919048
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
    Comella P; Casaretti R; De Vita F; Avallone A; Orditura M; Petrillo A; Gravina A; Faranda A; Comis S; Comella G; Catalano G
    Ann Oncol; 1999 Aug; 10(8):915-21. PubMed ID: 10509152
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Eniluracil treatment completely inactivates dihydropyrimidine dehydrogenase in colorectal tumors.
    Ahmed FY; Johnston SJ; Cassidy J; O'Kelly T; Binnie N; Murray GI; van Gennip AH; Abeling NG; Knight S; McLeod HL
    J Clin Oncol; 1999 Aug; 17(8):2439-45. PubMed ID: 10561307
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Final results of a prematurely discontinued Phase 1/2 study of eniluracil with escalating doses of 5-fluorouracil administered orally in patients with advanced hepatocellular carcinoma.
    de Lima Lopes G; Dicksey JS; Peters WP; Palalay M; Chang AY
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1067-73. PubMed ID: 21344302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.